Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 34 Issue 4
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2016  >  34(4): 366-371

ZHAO Jing, CAO Hong, XING Jun-bo. The fingerprint analysis on Chuanshentong injection by HPLC[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 137-139. doi: 10.3969/j.issn.1006-0111.2013.02.016
Citation: CAO Yue, YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 366-371. doi: 10.3969/j.issn.1006-0111.2016.04.022
shu

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

doi: 10.3969/j.issn.1006-0111.2016.04.022
  • 1.

    First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China

  • 2.

    Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

  • Received Date: 2016-04-08
  • Rev Recd Date: 2016-05-17
  • Objective To discuss dendritic cell-cytokine-induced killer (DC-CIK) cell therapy effects and clinical outcomes in patients with colorectal cancer in order to have better clinical treatment. Methods A retrospective analysis of the data of 66 patients with colorectal cancer from the Biological Therapy Department of the Eastern Hepatobiliary Surgery Hospital was performed from January 2012 to January 2014, and then was followed up. Taking gender, age, degree of pathological differentiation, TNM staging, surgical methods, and targeted therapy as the research basis, by the Kaplan-Meier single factor and Cox multiple factors analysis we mainly discuss the DC-CIK cell treatment's effect on the prognoses of patients. Results Kaplan-Meier single factor analysis results indicate:to a certain extent, DC-CIK cell therapy can improve the prognoses of patients; Cox multi-factor analysis results indicate whether accepting DC-CIK cell therapy is an independent factor influencing the prognoses of patients. Conclusion DC-CIK cells therapy can improve the prognoses of patients with colorectal cancer.
  • [1] 陈勇. 口服单药希罗达与FOLFOX方案治疗晚期结直肠癌的疗效比较[J]. 中国药业,2012,21(11):90-91.
    [2] Thara E, Dorff TB, Pinski JK, et al. Vaccine therapy with sipuleucel-T (provenge) for prostate cancer[J]. Maturitas,2011,69(4):296-303.
    [3] Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy[J]. J Transl Med,2011,9:214.
    [4] Bol KF, Tel J, de Vries IJM, et al. Naturally circulating dendritic cells to vaccinate cancer patients[J]. Oncoimmunology,2013,2(3):e23431.
    [5] Tel J, Smits EL, Anguille S, et al. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities[J]. Blood,2012,120(19):3936-3944.
    [6] Wang X, Yu W, Li H, et al. Can the dual-functional capability of CIK cells be used to improve antitumor effects?[J]. Cell Immunol,2014,287(1):18-22.
    [7] Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy[J]. Eur J Cell Biol,2012,91(1):53-58.
    [8] Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
    [9] Jakel CE, Hauser S, Rogenhofer S, et al. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma[J]. Clin Dev Immunol,2012,2012:473245.
    [10] Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
    [11] Shi S, Wang R, Chen Y, et al. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models[J]. PLoS One,2013,8(6):e65757.
    [12] Hasumi K, Aoki Y, Wantanabe R, et al. Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy[J]. Oncoimmunology,2013,2(10):e26381.
    [13] Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells:first report of the international registry on CIK cells (IRCC)[J]. J Cancer Res Clin Oncol,2011,137(2):305-310.
    [14] Thanendrarajan S, Nowak M, Abken H, et al. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy:more than one plus one?[J]. Leuk Res,2011,35(9):1136-1142.
    [15] Schlom J. Recent advances in therapeutic cancer vaccines[J]. Cancer Biother Radiopharm,2012,27(1):2-5.
    [16] Marten A, Renoth S, von Lilienfeld-Toal M, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells[J]. Haematologica,2001,86(10):1029-1037.
    [17] Xiang B, Snook AE, Magee MS, et al. Colorectal cancer immunotherapy[J]. Discov Med,2013,15(84):301-308.
    [18] Toomey PG, Vohra NA, Ghansah T, et al. Immunotherapy for gastrointestinal malignancies[J]. Cancer Control,2013,20(1):32-42.
    [19] Cui Y, Yang X, Zhu W, et al. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients[J]. Oncol Lett,2013,6(2):537-541.
    [20] Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
    [21] Duru N, Fan M, Candas D, et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells[J]. Clin Cancer Res,2012,18(24):6634-6647.
    [22] Beutler N, Hauka S, Niepel A, et al. A natural tapasin isoform lacking exon 3 modifies peptide loading complex function[J]. Eur J Immunol,2013,43(6):1459-1469.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-040Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 85.9 %FULLTEXT: 85.9 %META: 12.8 %META: 12.8 %PDF: 1.3 %PDF: 1.3 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 28.6 %其他: 28.6 %Singapore: 0.2 %Singapore: 0.2 %United States: 0.2 %United States: 0.2 %上海: 2.1 %上海: 2.1 %北京: 11.8 %北京: 11.8 %十堰: 0.2 %十堰: 0.2 %南京: 0.2 %南京: 0.2 %密蘇里城: 0.4 %密蘇里城: 0.4 %成都: 0.6 %成都: 0.6 %杭州: 0.6 %杭州: 0.6 %武汉: 0.2 %武汉: 0.2 %沈阳: 0.2 %沈阳: 0.2 %沧州: 0.2 %沧州: 0.2 %盐城: 0.2 %盐城: 0.2 %聊城: 0.4 %聊城: 0.4 %芒廷维尤: 13.9 %芒廷维尤: 13.9 %西宁: 37.4 %西宁: 37.4 %西安: 0.2 %西安: 0.2 %运城: 0.4 %运城: 0.4 %郑州: 0.2 %郑州: 0.2 %鄂州: 0.2 %鄂州: 0.2 %长沙: 0.2 %长沙: 0.2 %长治: 0.2 %长治: 0.2 %黄冈: 1.1 %黄冈: 1.1 %其他SingaporeUnited States上海北京十堰南京密蘇里城成都杭州武汉沈阳沧州盐城聊城芒廷维尤西宁西安运城郑州鄂州长沙长治黄冈Highcharts.com

  • Cited by

    Periodical cited type(8)

    1. 林新，王诗宝，何焕清，李钦艳，钟莹莹，陈逸湘，肖自添，凌宏通，曹斌，林苑云. 广东省梅州市紫灵芝产业现状与发展对策. 中国食用菌. 2023(04): 115-119 .
    2. 张碧云，陆敏. 灵芝在慢性萎缩性胃炎治疗中的应用进展. 云南中医中药杂志. 2022(09): 80-83 .
    3. 李亚晗，刘佳琳，王天添，刘玟妍，孙丽媛，李明成. 灵芝多糖抗肿瘤免疫调节机制的研究进展. 中国免疫学杂志. 2021(04): 511-514 .
    4. 赵玲. 灵芝多糖在运动员抗脂质过氧化中的作用. 中国食用菌. 2021(02): 75-79 .
    5. 田义敏，周欣，赵超，陈华国，龚小见. 中药有效成分抗胃癌作用机制的研究进展. 中国中药杂志. 2020(15): 3584-3593 .
    6. 王雪妍，周伏忠，向凌云，陈晓飞，宁萌，刁文涛. 灵芝免疫调节蛋白LZ-8及云芝免疫调节蛋白FIP-tvc对几种癌细胞系的抑制活性检测. 河南科学. 2019(06): 914-918 .
    7. 刘玲，李奇璋，周选围，王玉亮. 重组黑芝免疫调节蛋白对小鼠巨噬细胞RAW264.7向M1型分化的影响. 食品科学. 2019(23): 170-175 .
    8. 何嘉烽，吴小勇，尹辉，李文治，何文江. 水溶性灵芝粉的制备及其免疫调节活性评价. 广东药科大学学报. 2018(03): 288-292 .

    Other cited types(5)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(4332) PDF downloads(965) Cited by(13)

Related
Proportional views

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

doi: 10.3969/j.issn.1006-0111.2016.04.022
  • 1. First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China
  • 2. Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China
  • Received Date: 2016-04-08
  • Rev Recd Date: 2016-05-17

Abstract: Objective To discuss dendritic cell-cytokine-induced killer (DC-CIK) cell therapy effects and clinical outcomes in patients with colorectal cancer in order to have better clinical treatment. Methods A retrospective analysis of the data of 66 patients with colorectal cancer from the Biological Therapy Department of the Eastern Hepatobiliary Surgery Hospital was performed from January 2012 to January 2014, and then was followed up. Taking gender, age, degree of pathological differentiation, TNM staging, surgical methods, and targeted therapy as the research basis, by the Kaplan-Meier single factor and Cox multiple factors analysis we mainly discuss the DC-CIK cell treatment's effect on the prognoses of patients. Results Kaplan-Meier single factor analysis results indicate:to a certain extent, DC-CIK cell therapy can improve the prognoses of patients; Cox multi-factor analysis results indicate whether accepting DC-CIK cell therapy is an independent factor influencing the prognoses of patients. Conclusion DC-CIK cells therapy can improve the prognoses of patients with colorectal cancer.

ZHAO Jing, CAO Hong, XING Jun-bo. The fingerprint analysis on Chuanshentong injection by HPLC[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 137-139. doi: 10.3969/j.issn.1006-0111.2013.02.016
Citation: CAO Yue, YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 366-371. doi: 10.3969/j.issn.1006-0111.2016.04.022
shu

    HTML

Reference (22)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return